Cancer drugs funding

NICE recommends olaparib for advanced breast cancer in final draft guidance

The drug has previously been recommended for some types of ovarian cancer in England and for prostate cancer in Scotland.…

CAR-T infusions delivered to ‘more than 80’ patients in Wales, says NHS Wales

The NHS Wales Joint Commissioning Committee has enabled 100 patients in Wales to receive an advanced therapy medicinal product to date.…

Lung cancer: screening, diagnosis and management

An overview of the symptoms of suspected lung cancer, treatment strategies and current national screening programmes and pilots.…

Thousands of NHS patients with prostate or breast cancer eligible for new targeted treatment

NHS England says around 800 people in England could be eligible for olaparib treatment each year.…

NHS patients will be first in Europe to receive mutation-targeting lung cancer treatment

The tumour-agnostic drug sotorasib has been approved for the treatment of patients in England with non-small cell lung cancer.…

The most innovative cancer drugs take longest to reach patients, study suggests

The most innovative new cancer drugs are taking longer to pass through clinical trials, licensing and eventual appraisal by the National Institute for Health and Care Excellence, an analysis carried out by the Institute of Cancer Research has suggested.…

NHS patients waiting longer for new cancer drugs

Patients are waiting almost a year and a half longer for new cancer drugs to be made available on the NHS than they were a decade ago, a report from the Institute of Cancer Research has found.…

Multiple myeloma drug approved for use within the Cancer Drugs Fund

The proteasome inhibitor ixazomib, marketed as Ninlaro, has received approval for use within the Cancer Drugs Fund for patients with multiple myeloma.…

NICE asks Merck to submit Cancer Drugs Fund proposal for immunotherapy drug

The National Institute for Health and Care Excellence has asked pharmaceutical company, Merck, to submit a Cancer Drugs Fund proposal for its immunotherapy drug avelumab (Bavencio; Merck)…

Nivolumab to be made available to lung cancer patients in England and Wales, says NICE

NICE agrees to make immunotherapy drug nivolumab available to lung cancer patients in England and Wales.…